A meta-analysis of lipid peroxidation markers in major depression

QR Code

A meta-analysis of lipid peroxidation markers in major depression

Graham Mazereeuw,1,2 Nathan Herrmann,1,3 Ana C Andreazza,2–4 Maisha M Khan,1 Krista L Lanctôt1–3 1Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 2Department of Pharmacology and Toxicology, Universi...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, Lanctôt KL
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2015
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/3ed4a0d0636b4b17a50f1096de2ab5cc
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study
par: Mazereeuw G, et autres
Publié: (2015)

Kynurenine and depressive symptoms in a poststroke population
par: Bensimon K, et autres
Publié: (2014)

Desvenlafaxine in the treatment of major depressive disorder
par: Maria Teresa C Lourenco1, et autres
Publié: (2009)

Psychiatric comorbidities in patients with major depressive disorder
par: Thaipisuttikul P, et autres
Publié: (2014)

Transcranial magnetic stimulation for the treatment of major depression
par: Janicak PG, et autres
Publié: (2015)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
par: Han Y, et autres
Publié: (2016)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
par: Dannehl K, et autres
Publié: (2014)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
par: Mazen K Ali, et autres
Publié: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
par: J Craig Nelson, et autres
Publié: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
par: Tobe EH
Publié: (2013)

The cortisol awakening response and major depression: examining the evidence
par: Dedovic K, et autres
Publié: (2015)

Levomilnacipran for the treatment of major depressive disorder: a review
par: Asnis GA, et autres
Publié: (2015)

Is placebo useful in the treatment of major depression in clinical practice?
par: Marchesi C, et autres
Publié: (2013)

Psychomotor retardation and externally oriented thinking in major depression
par: Luca M, et autres
Publié: (2013)

Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review
par: Chen YW, et autres
Publié: (2015)

Synaptic proteins in CSF relate to Parkinson’s disease stage markers
par: Erika Bereczki, et autres
Publié: (2017)

Major depressive disorder: mechanism-based prescribing for personalized medicine
par: Saltiel PF, et autres
Publié: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
par: Yang X, et autres
Publié: (2015)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
par: Pecenak J, et autres
Publié: (2013)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
par: Zhang XF, et autres
Publié: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
par: Alvarez E, et autres
Publié: (2014)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
par: Marty Hinz, et autres
Publié: (2010)

Serum lipid profile among sporadic and familial forms of Parkinson’s disease
par: Daniel Macías-García, et autres
Publié: (2021)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
par: Maneeton B, et autres
Publié: (2018)

Shared genetic etiology between Parkinson’s disease and blood levels of specific lipids
par: Helena Xicoy, et autres
Publié: (2021)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
par: Armaly Z, et autres
Publié: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
par: Bojana Perovic, et autres
Publié: (2010)

Age-associated decrease in global DNA methylation in patients with major depression
par: Tseng PT, et autres
Publié: (2014)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
par: Pecenak J, et autres
Publié: (2013)

“Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C
par: Shuzhen Zhu, et autres
Publié: (2021)

Cilostazol for secondary stroke prevention: systematic review and meta-analysis
par: Leonard LL Yeo, et autres
Publié: (2021)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
par: Kamijima K, et autres
Publié: (2013)

Recurrent major depression, ataxia, and cardiomyopathy: association with a novel POLG mutation?
par: Verhoeven WMA, et autres
Publié: (2011)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
par: Baskaran A, et autres
Publié: (2013)

Subthalamic and pallidal deep brain stimulation for Parkinson’s disease—meta-analysis of outcomes
par: M. Lenard Lachenmayer, et autres
Publié: (2021)

Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis
par: Jia-Hung Chen, et autres
Publié: (2021)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
par: Wu MK, et autres
Publié: (2015)

Differential clinical effects of fluvoxamine by the effect of age in Japanese female major depressive patients
par: Hisashi Higuchi, et autres
Publié: (2009)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
par: Kamijima K, et autres
Publié: (2013)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
par: Demir S, et autres
Publié: (2015)